Enovis Management

Management criteria checks 3/4

Enovis' CEO is Matt Trerotola, appointed in Jul 2015, has a tenure of 8.75 years. total yearly compensation is $10.77M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth €9.23M. The average tenure of the management team and the board of directors is 5.3 years and 3.7 years respectively.

Key information

Matt Trerotola

Chief executive officer

US$10.8m

Total compensation

CEO salary percentage	10.0%
CEO tenure	8.8yrs
CEO ownership	0.3%
Management average tenure	5.3yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Matt Trerotola's remuneration changed compared to Enovis's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$11m	US$1m	-US$54m
Sep 29 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$159m
Mar 31 2023	n/a	n/a	-US$23m
Dec 31 2022	US$12m	US$1m	-US$39m
Sep 30 2022	n/a	n/a	US$1m
Jul 01 2022	n/a	n/a	US$54m
Apr 01 2022	n/a	n/a	-US$109m
Dec 31 2021	US$14m	US$1m	-US$103m
Oct 01 2021	n/a	n/a	-US$48m
Jul 02 2021	n/a	n/a	-US$18m
Apr 02 2021	n/a	n/a	US$21m
Dec 31 2020	US$8m	US$1m	-US$75m
Oct 02 2020	n/a	n/a	US$53m
Jul 03 2020	n/a	n/a	US$39m
Apr 03 2020	n/a	n/a	US$42m
Dec 31 2019	US$8m	US$1m	US$8m
Sep 27 2019	n/a	n/a	US$10m
Jun 28 2019	n/a	n/a	US$21m
Mar 29 2019	n/a	n/a	US$66m
Dec 31 2018	US$3m	US$1m	US$108m
Sep 28 2018	n/a	n/a	-US$115m
Jun 29 2018	n/a	n/a	-US$84m
Mar 30 2018	n/a	n/a	-US$92m
Dec 31 2017	US$3m	US$1m	US$28m

Compensation vs Market: Matt's total compensation ($USD10.77M) is above average for companies of similar size in the German market ($USD2.56M).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.

CEO

Matt Trerotola (56 yo)

8.8yrs

Tenure

US$10,774,635

Compensation

Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Matthew Trerotola	CEO & Chairman	8.8yrs	US$10.77m	0.33% $ 9.2m
Phillip Berry	Senior VP & CFO	1.3yrs	US$2.36m	0.018% $ 502.6k
Patricia Lang	Senior VP & Chief Human Resources Officer	5.3yrs	US$2.07m	0.041% $ 1.2m
Daniel Pryor	Executive Vice President of Strategy & Business Development	10.8yrs	US$4.75m	0.16% $ 4.4m
Brady Shirley	Executive Advisor & Director	7.4yrs	US$5.20m	0.11% $ 3.2m
John Kleckner	VP, Controller & Chief Accounting Officer	1.9yrs	no data	0.012% $ 346.0k
Derek Leckow	Vice President of Investor Relations	no data	no data	no data
Bradley Tandy	Senior VP & Chief Legal Officer	5.2yrs	no data	0.046% $ 1.3m
Katie Sweet	Vice President of Corporate Communication	no data	no data	no data
Terry Ross	Group President Prevention & Recovery	no data	no data	0.036% $ 1.0m
Brian Hanigan	Secretary	no data	no data	no data
Louie Vogt	Group President of Reconstructive	no data	no data	0.044% $ 1.3m

5.3yrs

Average Tenure

55yo

Average Age

Experienced Management: C520's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Matthew Trerotola	CEO & Chairman	8.8yrs	US$10.77m	0.33% $ 9.2m
Brady Shirley	Executive Advisor & Director	2yrs	US$5.20m	0.11% $ 3.2m
Sharon Wienbar	Lead Independent Director	7.8yrs	US$316.46k	0% $ 0
A. Perfall	Independent Director	13.6yrs	US$308.93k	0.0045% $ 128.0k
Angela Lalor	Independent Director	2yrs	US$296.46k	0.012% $ 349.4k
Rajiv Vinnakota	Independent Director	15.9yrs	US$298.93k	0.012% $ 340.6k
Liam Kelly	Independent Director	4.3yrs	US$283.93k	0.016% $ 446.9k
Philip Okala	Independent Director	3.2yrs	US$283.93k	0.0067% $ 190.8k
Barbara Bodem	Independent Director	2yrs	US$283.93k	0.0072% $ 202.1k
Christine Ortiz	Independent Director	2yrs	US$283.93k	0.0072% $ 202.1k

3.7yrs

Average Tenure

56yo

Average Age

Experienced Board: C520's board of directors are considered experienced (3.7 years average tenure).

Enovis Management

Management criteria checks 3/4

Key information

Recent management updates

Enovis Corporation, Annual General Meeting, May 20, 2024

Enovis Corporation Announces Leadership Transition Plan

High number of new directors

Enovis Corporation Announces That Ben Berry, CFO of the Company's Business Units, Will Succeed Chris Hix as Chief Financial Officer, Effective January 1, 2023

High number of new directors

High number of new directors

Recent updates

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.99 loss per share (vs US$0.72 loss in FY 2022)

Enovis Corporation Provides Earnings Guidance for the Year 2024

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

No longer forecast to breakeven

Enovis Corporation Announces Leadership Transition Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$1.22 loss in 3Q 2022)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Now 21% undervalued

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$2.23 profit in 2Q 2022)

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.71 loss in 1Q 2022)

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.84 profit in FY 2021)

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings released: US$1.22 loss per share (vs US$0.51 profit in 3Q 2021)

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: EPS: US$2.23 (vs US$0.59 in 2Q 2021)

Enovis Launches ARVIS®, Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery

Enovis Corporation to Report Q2, 2022 Results on Aug 04, 2022

Enovis Corporation (NYSE:ENOV) acquired Insight Medical Systems, Inc.

Enovis Corporation Announces That Ben Berry, CFO of the Company's Business Units, Will Succeed Chris Hix as Chief Financial Officer, Effective January 1, 2023

Enovis Corporation Launches Arsenal Ankle Plating System

High number of new directors

Enovis Corporation Reaffirms Revenue Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.57 in 1Q 2021)

High number of new directors

Enovis Corporation to Report Q1, 2022 Results on May 10, 2022

Enovis Corporation Announces Board Changes

Investor sentiment deteriorated over the past week

Enovis Corporation completed the Spin-Off of ESAB Corporation (NYSE:ESAB).

Colfax Corporation Announces Board Resignations, Effective Upon the Consummation of the Separation of its Fabrication Technology Business

Executive VP of Finance & CFO recently sold €64k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Colfax Corporation Provides Earnings Guidance for the Year 2022

Colfax Corporation Announces Management Changes, Effective May 13, 2022

Third quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 in 3Q 2020)

Independent Director recently sold €88k worth of stock

Co-Founder & Chairman of the Board recently bought €9.8m worth of stock

Second quarter 2021 earnings released: EPS US$0.20 (vs US$0.026 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.057 in 1Q 2020)

Colfax Corporation has completed a Follow-on Equity Offering in the amount of $644 million.

Colfax Corporation Announces Executive Changes for Two Differentiated, Independent, and Publicly-Traded Companies

Colfax Corporation Appoints Philip Okala to its Board of Directors

New 90-day high: €35.20

Full year 2020 earnings released: EPS US$0.44 (vs US$0.062 in FY 2019)

Revenue beats expectations

Colfax Corporation to Report Q4, 2020 Results on Feb 18, 2021

New 90-day high: €32.80

New 90-day high: €29.40

Colfax Corporation (NYSE:CFX) entered into an agreement to acquire certain extremity product lines from Stryker Corporation (NYSE:SYK) for $15 million.

Colfax Corporation to Report Q3, 2020 Results on Oct 29, 2020

Colfax Corporation announced that it expects to receive $805.000055 million in funding from BDT Capital Partners, LLC, Markel Corporation

Colfax Corporation Not Providing Financial Guidance for the year 2020

New 90-day high - €29.00

First half earnings released